Skip to content

Vor Biopharma VOR Free cash flow

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.29B+66.4%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$28.87M-4.4%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$16.43M+2.6%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.32M+9.7%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Calculated from Vor Biopharma’s reported figures.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's free cash flow?
Vor Biopharma (VOR) reported free cash flow of -$38.29M in Q1 2026.
How has Vor Biopharma's free cash flow changed year-over-year?
Vor Biopharma's free cash flow decreased by 22.4% year-over-year, from -$31.3M to -$38.29M.
What is the long-term trend for Vor Biopharma's free cash flow?
Over 4 years (2021 to 2025), Vor Biopharma's free cash flow has grown at a 18.4% compound annual growth rate (CAGR), from -$73.04M to -$143.65M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.